Garmin and Cheesecake Factory posted strong earnings beats and raised guidance, but non-recurring items and margin pressures suggest their stock rallies may be losing steam.
Snow and ice equipment company Douglas Dynamics (NYSE:PLOW) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 10.5% year on year t...
The consensus bottom-line forecasts most investors were comparing its results to didn't appear to factor in changes stemming from a recent spinoff, or any one-time costs related to it.
Marriott International (NASDAQ:MAR) reported second-quarter results that exceeded its prior expectations, driven by global revenue per available room growth, expanding fee revenue and continued portfolio growth. The company raised its full-year 2026 outlook for global RevPAR, gross fee revenue, adju
Sportradar Group (NASDAQ:SRAD) reported second-quarter revenue growth of 19% as demand for its betting content, streaming, data and engagement products remained strong, while the company lowered its full-year outlook to reflect slower traditional U.S. sportsbook growth, regulatory and tax headwinds
Supernus Pharmaceuticals (NASDAQ:SUPN) and Indivior Pharmaceuticals announced a proposed all-stock, tax-free merger of equals that would create a central nervous system-focused biopharmaceutical company with approximately $2.2 billion in pro forma trailing 12-month net revenue as of June 30, 2026.
TG Therapeutics (NASDAQ:TGTX) reported second-quarter 2026 revenue of $240 million and raised its full-year sales outlook for BRIUMVI, its treatment for relapsing multiple sclerosis, as the company cited record new patient starts, continued prescriber expansion and higher-than-expected treatment per
Johnson & Johnson (NYSE:JNJ) outlined its commercialization plans for the OTTAVA robotic surgical system after receiving U.S. Food and Drug Administration De Novo authorization, positioning the table-integrated platform as a long-term growth initiative in surgical robotics.
The company said it
Compugen (NASDAQ:CGEN) said its second-quarter 2026 progress included continued enrollment in its MAIA-ovarian study of COM701, advancing partner-led programs with AstraZeneca and Gilead, and a cash runway projected to extend into 2029.
President and Chief Executive Officer Eran Ophir described the
Supernus Pharmaceuticals and Indivior (NASDAQ:INDV) announced plans to combine in an all-stock, tax-free merger of equals that the companies said would create a central nervous system-focused biopharmaceutical company with approximately $2.2 billion in pro forma trailing-12-month net revenue.
The t
Krystal Biotech (NASDAQ:KRYS) reported second-quarter 2026 net revenue of $119.2 million from global sales of VYJUVEK, up 24% from $96 million in the prior-year period, as the company expanded treatment access for patients with dystrophic epidermolysis bullosa, or DEB, in the United States and overs
Lindblad Expeditions (NASDAQ:LIND) reported higher second-quarter revenue, occupancy and adjusted EBITDA, while raising its full-year revenue and net-yield outlook amid continued elevated fuel costs.
Total revenue increased 19% year over year to $199.2 million in the second quarter of 2026. Adjuste
BCB Bancorp, Inc. (NJ) (NASDAQ:BCBP) said it is continuing a broad review of its loan portfolios, capital position and holding-company structure as new President and CEO Thomas O’Brien works to address credit issues tied to prior years of aggressive growth.
O’Brien, who said the earnings call marke
American Bitcoin (NASDAQ:ABTC) reported higher second-quarter Bitcoin production and revenue as the company brought its Drumheller facility online at scale, while a decline in Bitcoin prices contributed to a GAAP net loss tied largely to fair-value accounting for its digital-asset holdings.
The com
The semiconductor-heavy MSCI Asia Pacific index has lost about 10% of its value since June 22. Is this a temporary dip or a long-term repricing for chip stocks?
McKesson, Encompass Health and Omega Healthcare Investors raised dividends, with payout ratios and yields showing varying levels of sustainability across the healthcare sector.
Which hyperscaler's balance sheet could ride out a rough stretch, and which couldn't? The gap between Microsoft and Oracle is wider than their spending suggests.
Russell Hutchinson disposed of 12,614 shares following restricted stock unit vesting, retaining direct ownership of 241,253 shares worth $10.72 million.
